COMPARATIVE EFFICACY AND SAFETY OF FIRST-LINE SYSTEMIC COMBINATIONS IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC): A BAYESIAN NETWORK META-ANALYSIS OF 11 PHASE III TRIALS (AASLD 2026) - Oct 6, 2026 - Abstract #154; "Sintilimab plus bevacizumab (HR 0.57, 95% CrI 0.44–0.75), atezolizumab plus bevacizumab (HR 0.58, 0.43–0.79), and camrelizumab plus rivoceranib (HR 0.62, 0.49–0.80) showed the most significant OS improvements compared with sorafenib. Dual immune checkpoint blockade (ICI–ICI) regimens, including nivolumab plus ipilimumab (HR 0.79, 0.65–0.96) and durvalumab plus tremelimumab (HR 0.78, 0.65–0.93), also improved OS but ranked lower than ICI–anti-VEGF/ ICI–TKI strategies.For PFS (low-to-moderate GRADE certainty), ICI–TKI regimens such as penpulimab plus anlotinib (HR 0.52, 0.41–0.66) showed the highest probability of being the best treatment.Regarding safety, distinct toxicity profiles emerged... This network meta-analysis shows that multiple combination strategies significantly outperform standard-of-care TKIs in first-line uHCC, with distinct efficacy and safety profiles. ICI–anti-VEGF and selected ICI–TKI combinations provide the greatest survival benefit but..."
P3 data • Retrospective data • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatocellular Cancer • Hepatology • Hypertension • Immunology • Inflammation • Oncology • Solid Tumor
|
|
Rahul Falodia1; Maheen Afzal2; Ubaid Ahmed3
|